Category: cancer therapeutics

Squamous Non Small Cell Lung Cancer Market: Current Scenario

Close to 1.8 million fatalities reported in 2020 were observed to be associated with lung cancer, which is believed to be one of the most aggressive forms of carcinoma, globally. One of the primary reasons for the high mortality rate associated with this condition is anticipated to be improper liquid biopsy, which eventually results in

Myeloid Cell Targeting Therapies: Budding Therapy Against Cancer

The global cancer burden is increasing rapidly with over 19 million new cancer cases and 10 million deaths reported in the year 2020. Given the rising prevalence, researchers have made significant efforts in discovering new approaches for the treatment of oncological diseases using cell and gene therapy solutions. With several programs having entered the clinical

TIL Therapies: A New Paradigm in Cancer Treatment

Modified tumor-infiltrating lymphocytes or TIL therapies have emerged as a viable and potent option to selectively eradicate the tumor population, with minimal side effects. Till date, several clinical trials have demonstrated the efficacy and therapeutic superiority (over conventional treatment options) of TIL-based therapies. Their tumor-cell killing efficiency is attributed to the fact that they are

AI Cancer Treatment: Current Scenario And Future Potential

In the last decade, the popularity of AI has grown invariably. Specifically, it has made a considerable impact in the medical sector and oncologic treatment as well, due to a surge in electronic data, breakthroughs in technological infrastructure and groundbreaking research in deep learning neural networks. AI cancer treatment has demonstrated potential in improving liquid

HER2 Targeted Therapy: Market Landscape and Future Potential

The epidermal growth factor receptor (EGFR) is a tumor resistance biomarker which plays an essential role in the differentiation and proliferation upon activation through the binding of one of its ligands. A non-ligand-binding member of EGFR family, HER2 exerts its activity through heterodimerisation along with its other family members. HER2 targeted therapy affects the transmembrane

Immune Checkpoint Inhibitors: Another Big Opportunity

There is an urgent unmet need for developing innovative and effective cancer therapeutics for the treatment of patients with late-stage and refractory cancer. Amidst the widespread initiatives to develop more targeted anti-cancer therapies, immune checkpoint inhibitors emerged as a highly specific and potent option to eradicate tumor cells with minimal side effects. Once the body